Search

Your search keyword '"Cuk K."' showing total 86 results

Search Constraints

Start Over You searched for: Author "Cuk K." Remove constraint Author: "Cuk K."
86 results on '"Cuk K."'

Search Results

1. Development and validation of a panel of five proteins as blood biomarkers for early detection of colorectal cancer

2. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (Nature Genetics, (2021), 53, 1, (65-75), 10.1038/s41588-020-00748-0).

3. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.

4. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

5. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

6. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.

7. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study

8. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma

9. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma

10. Germline variation at 8q24 and prostate cancer risk in men of European ancestry (vol 9, 4616, 2018)

11. Discovery of common and rare genetic risk variants for colorectal cancer

12. Correction to: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (Nature Genetics, (2018), 50, 7, (928-936), 10.1038/s41588-018-0142-8).

13. Germline variation at 8q24 and prostate cancer risk in men of European ancestry.

14. Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1).

15. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (Nature Genetics, (2018), 50, 7, (928-936), 10.1038/s41588-018-0142-8).

16. Discovery of common and rare genetic risk variants for colorectal cancer

17. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma

18. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

19. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation

20. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma

21. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

22. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

23. E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium

24. E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium

25. E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium

26. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation

27. rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk

29. rs2735383, located at a microRNA binding site in the 3 ' UTR of NBS1, is not associated with breast cancer risk

32. rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk

33. Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control study.

34. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.

35. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.

36. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.

37. Factors associated with false-positive fecal immunochemical tests in a large German colorectal cancer screening study.

38. Investigation on potential associations of oxidatively generated DNA/RNA damage with lung, colorectal, breast, prostate and total cancer incidence.

39. Circulating MicroRNA Biomarkers for Lung Cancer Detection in East Asian Populations.

40. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study.

41. Whole-Blood DNA Methylation Markers in Early Detection of Breast Cancer: A Systematic Literature Review.

42. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

43. Combination of Different Fecal Immunochemical Tests in Colorectal Cancer Screening: Any Gain in Diagnostic Performance?

44. Discovery of common and rare genetic risk variants for colorectal cancer.

45. Fecal immunochemical test for hemoglobin in combination with fecal transferrin in colorectal cancer screening.

46. Circulating microRNA biomarkers for lung cancer detection in Western populations.

47. Urinary 8-isoprostane levels and occurrence of lung, colorectal, prostate, breast and overall cancer: Results from a large, population-based cohort study with 14 years of follow-up.

48. Direct comparison of ten quantitative fecal immunochemical tests for hemoglobin stability in colorectal cancer screening.

49. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

50. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

Catalog

Books, media, physical & digital resources